Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2521256 | 1.00 | HSD11B1 (0.39) | HSD11B1SLC6A1SLC6A11TSHRLMNA | |
| SCHEMBL715627 | 1.00 | HSD11B1 (0.39) | HSD11B1SLC6A1SLC6A11TSHRLMNA | |
| Oxalic Acid SCHEMBL4013440 | 0.96 | HSD11B1 (0.37) | HSD11B1SLC6A1SLC6A11TSHRLMNA | |
| Oxalic Acid SCHEMBL1624265 | 0.96 | HSD11B1 (0.37) | HSD11B1SLC6A1SLC6A11TSHRLMNA | |
| SCHEMBL181909 | 0.90 | SLC6A4 (0.42) | HSD11B1SLC6A4SLC6A2KCNH2SLC6A3 | |
| SCHEMBL1033810 | 0.90 | SLC6A4 (0.42) | HSD11B1SLC6A4SLC6A2KCNH2SLC6A3 | |
| SCHEMBL65492 | 0.90 | SLC6A4 (0.42) | HSD11B1SLC6A4SLC6A2KCNH2SLC6A3 | |
| Hydrochloric Acid SCHEMBL25408690 | 0.89 | SLC6A4 (0.41) | HSD11B1SLC6A4SLC6A2KCNH2SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL19410295 | 0.89 | SLC6A4 (0.41) | HSD11B1SLC6A4SLC6A2KCNH2SLC6A3 | |
| Hydrochloric Acid SCHEMBL31485474 | 0.89 | SLC6A4 (0.41) | HSD11B1SLC6A4SLC6A2KCNH2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12595244-B2 | Small molecule inhibitors of mammalian SLC6A19 function | JNANA THERAPEUTICS INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260001859-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | JNANA THERAPEUTICS INC. | 2026-01-01 | — | — | US | disclosed |
| US-12479845-B2 | Imidazopyridine derivative compounds and use of same | HANMI PHARM. CO., LTD. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4622960-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250289798-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | JNANA THERAPEUTICS INC. | 2025-09-18 | — | — | US | disclosed |
| WO-2009029632-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009029632-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2009016410-A2 | CHEMICAL COMPOUNDS 831 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| EP-1784393-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| WO-2006028904-A9 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006028904-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595244-B2 | Small molecule inhibitors of mammalian SLC6A19 function | SLC6A19, SLC6A15, SLC19A1 | HSD11B1 937/4885SLC6A1 56/4885SLC6A11 69/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | HSD11B1 3158/4885SLC6A1 3624/4885SLC6A11 2597/4885 |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | HSD11B1 2999/4885SLC6A1 4592/4885SLC6A11 4242/4885 |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | HSD11B1 4751/4885SLC6A1 174/4885SLC6A11 206/4885 |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | CLIC1, HCCS, CNR1 | HSD11B1 1512/4885SLC6A1 354/4885SLC6A11 761/4885 |
| US-20250289798-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | SLC18A2, SLC6A19, SLC1A1 | HSD11B1 2156/4885SLC6A1 14/4885SLC6A11 38/4885 |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | HSD11B1 161/4885SLC6A1 572/4885SLC6A11 996/4885 |
| US-12479845-B2 | Imidazopyridine derivative compounds and use of same | KDM1A, KDM1B, KDM2A | HSD11B1 556/4885SLC6A1 2519/4885SLC6A11 2680/4885 |
| US-20260001859-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | SLC6A19, SLC6A15, SLC6A2 | HSD11B1 356/4885SLC6A1 4/4885SLC6A11 19/4885 |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | CBR1, CLIC1, RER1 | HSD11B1 1968/4885SLC6A1 435/4885SLC6A11 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.